Engineering a versatile and retrievable cell macroencapsulation device for the delivery of therapeutic proteins.
Natural sciences
Pharmaceutical science
Pharmacology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
18 Aug 2023
18 Aug 2023
Historique:
received:
22
05
2023
revised:
12
06
2023
accepted:
10
07
2023
medline:
4
8
2023
pubmed:
4
8
2023
entrez:
4
8
2023
Statut:
epublish
Résumé
Encapsulated cell therapy holds a great potential to deliver sustained levels of highly potent therapeutic proteins to patients and improve chronic disease management. A versatile encapsulation device that is biocompatible, scalable, and easy to administer, retrieve, or replace has yet to be validated for clinical applications. Here, we report on a cargo-agnostic, macroencapsulation device with optimized features for protein delivery. It is compatible with adherent and suspension cells, and can be administered and retrieved without burdensome surgical procedures. We characterized its biocompatibility and showed that different cell lines producing different therapeutic proteins can be combined in the device. We demonstrated the ability of cytokine-secreting cells encapsulated in our device and implanted in human skin to mobilize and activate antigen-presenting cells, which could potentially serve as an effective adjuvant strategy in cancer immunization therapies. We believe that our device may contribute to cell therapies for cancer, metabolic disorders, and protein-deficient diseases.
Identifiants
pubmed: 37539029
doi: 10.1016/j.isci.2023.107372
pii: S2589-0042(23)01449-9
pmc: PMC10393802
doi:
Types de publication
Journal Article
Langues
eng
Pagination
107372Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
N.M. is founder and stockholder of MaxiVAX SA, one of the sponsors of this work. J.G., E.C., and A.E. are employees of MaxiVAX SA. A.L. is a former employee of MaxiVAX SA. A.L., J.G., and N.M. are inventors in a patent related to this work. MaxiVAX SA is a Geneva-based biotech company involved in cell encapsulation technology.
Références
Nat Biotechnol. 2005 Jan;23(1):47-55
pubmed: 15637621
Biostatistics. 2008 Apr;9(2):321-32
pubmed: 17728317
Vaccines (Basel). 2021 May 10;9(5):
pubmed: 34068677
Mol Ther Methods Clin Dev. 2022 Aug 01;26:441-458
pubmed: 36092361
Expert Rev Vaccines. 2010 May;9(5):519-25
pubmed: 20450326
Adv Drug Deliv Rev. 2019 Jan 15;139:92-115
pubmed: 29719210
Immunotherapy. 2017 Mar;9(4):347-360
pubmed: 28303764
Dent Mater. 2013 Sep;29(9):e169-79
pubmed: 23849746
Cancer Immunol Immunother. 2022 Sep;71(9):2267-2275
pubmed: 35133464
Int J Mol Sci. 2015 May 08;16(5):10578-600
pubmed: 26006227
Cancer Gene Ther. 2006 Jun;13(6):555-62
pubmed: 16410826
Brain. 2016 May;139(Pt 5):1587-604
pubmed: 26956423
Biomaterials. 2016 Dec;110:11-23
pubmed: 27697668
J Clin Oncol. 1995 Jan;13(1):264-73
pubmed: 7799030
Tissue Eng Part A. 2010 May;16(5):1503-13
pubmed: 20001535
J Immunol. 2008 Dec 15;181(12):8576-84
pubmed: 19050277
Adv Ther (Weinh). 2020 Sep;3(9):
pubmed: 33072860
Cancer Gene Ther. 2011 Aug;18(8):553-62
pubmed: 21566667
Cell. 1999 Oct 1;99(1):23-33
pubmed: 10520991
Sci Rep. 2014 Oct 31;4:6856
pubmed: 25358640
Sci Adv. 2022 Mar 4;8(9):eabm1032
pubmed: 35235346
Immunol Rev. 2002 Oct;188:147-54
pubmed: 12445288
Biomaterials. 2014 Jan;35(2):779-91
pubmed: 24103654
Biotechnol J. 2017 Sep;12(9):
pubmed: 28734022
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Trends Pharmacol Sci. 2015 Aug;36(8):537-46
pubmed: 26067102
Nat Biomed Eng. 2020 Aug;4(8):814-826
pubmed: 32231313
Front Pharmacol. 2018 Jun 26;9:642
pubmed: 29997500
Biomaterials. 2006 Apr;27(12):2609-20
pubmed: 16364430
Front Immunol. 2022 Jul 05;13:901277
pubmed: 35865534
Nat Rev Drug Discov. 2022 Sep;21(9):655-675
pubmed: 35637318
Int Immunol. 2015 Jan;27(1):11-20
pubmed: 25087232
J Invest Surg. 2012 Oct;25(5):330-9
pubmed: 22571739
Sci Adv. 2023 Jun 9;9(23):eadf9491
pubmed: 37285432
Nucleic Acids Res. 2021 Jan 8;49(D1):D325-D334
pubmed: 33290552
J Infect Dis. 2018 Nov 22;218(suppl_5):S519-S527
pubmed: 30053157
Drug Discov Today. 2021 Mar;26(3):852-861
pubmed: 33242694
Prog Retin Eye Res. 2019 Jan;68:67-82
pubmed: 30342088
Blood. 2012 Apr 12;119(15):3383-93
pubmed: 22323450
Adv Drug Deliv Rev. 2014 Apr;67-68:3-14
pubmed: 23886766
Cancer Res. 2013 Jun 15;73(12):3591-603
pubmed: 23633484
Cell. 1992 Mar 6;68(5):855-67
pubmed: 1547487
J Interferon Cytokine Res. 2015 Aug;35(8):585-99
pubmed: 25803788
J Immunol Methods. 2011 Oct 28;373(1-2):192-9
pubmed: 21903095
Oncoimmunology. 2015 Oct 29;5(4):e1101204
pubmed: 27141383
Front Med (Lausanne). 2020 Nov 26;7:592242
pubmed: 33324662
Int Arch Allergy Immunol. 1993;102(3):242-8
pubmed: 8219777
J Immunol. 2011 Mar 15;186(6):3364-72
pubmed: 21296980
J Control Release. 2002 Jan 17;78(1-3):15-24
pubmed: 11772445
Chem Soc Rev. 2017 Nov 13;46(22):6764-6815
pubmed: 28875205
Ann Oncol. 2007 Feb;18(2):226-32
pubmed: 17116643
Cancer Res. 2004 Sep 1;64(17):6337-43
pubmed: 15342423
Methods Mol Biol. 2020;2100:473-491
pubmed: 31939144
Biotechnol Bioeng. 2016 Jul;113(7):1381-402
pubmed: 26615050
Nucleic Acids Res. 2019 Jan 8;47(D1):D330-D338
pubmed: 30395331
Tissue Eng. 2007 Aug;13(8):2133-41
pubmed: 17516853
J Biol Regul Homeost Agents. 2001 Apr-Jun;15(2):163-5
pubmed: 11501974
Front Bioeng Biotechnol. 2019 Sep 27;7:247
pubmed: 31637236
Ophthalmology. 2019 Apr;126(4):540-549
pubmed: 30292541
Nat Rev Immunol. 2002 Apr;2(4):251-62
pubmed: 12001996
Sci Rep. 2017 Mar 28;7(1):491
pubmed: 28352127
J Funct Biomater. 2021 Nov 30;12(4):
pubmed: 34940547
Adv Physiol Educ. 2013 Dec;37(4):284-91
pubmed: 24292903
Cell Mol Immunol. 2018 Feb;15(2):187-189
pubmed: 29057973